OssDsign
OverviewSuggest Edit
OssDsign is a medtech company dedicated to creating regenerative implants for improved healing of bone defects. The company provides neurosurgeons and reconstructive plastic surgeons with a range of implant solutions. Its products include OSSDSIGN Cranial, an implant solution for cranioplasty patients; OSSDSIGN Facial to treat complex facial skeletal defects; and OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage.
| Type | Public | |
| Founded | 2011 | |
| HQ | Uppsala, SE | Map |
| Website | ossdsign.com |
Recent NewsAll News
- Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI
- Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst
- Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market
- OssDsign Partners with Red One Medical to Provide Reconstructive Cranial Solutions and Synthetic Bone Grafts to US Veterans and Military Members
Latest Updates
| Employees (est.) (Feb 2020) | 40 | |
| Cybersecurity rating | B | More |
Key People/Management at OssDsign
Anders Qvarnström
Director
Simon Cartmell
Director and Chairman
Morten Henneveld
CEO
Newton Aguiar
Director
Viktor Drvota
Director
Kajsa Björklund
Director Technical Operations
OssDsign Office Locations
OssDsign has an office in Uppsala
Uppsala, SE (HQ)
Uppsala Business Park Rapsgatan 7 Postal Address:, Virdings allé 2
Uppsala, SE
Rapsgatan 23
OssDsign Online and Social Media Presence
348 Twitter followers
OssDsign has 348 Twitter Followers. The number of followers has increased 1.3% month over month and increased 2.5% quarter over quarter
OssDsign's Trends
Twitter Engagement Stats for @OssDsign
380
Tweets
312
Following
348
Followers
6
Tweets last 30 days
6.8
Avg. likes per Tweet
100%
Tweets with engagement
OssDsign News and Updates
October 04, 2021
Karolinska Development's portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI
STOCKHOLM, SWEDEN, 4 October 2021 Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign AB has received an expanded marketing authorization from the U.S. Food and Drug Administration (FDA) for the company's patient-specific cranial implant product Oss…
September 09, 2021
Karolinska Development's portfolio company OssDsign includes first patient to a clinical trial of the synthetic bone graft OssDsign Catalyst
STOCKHOLM, SWEDEN – September 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has included the first patient to the clinical trial TOP FUSION which aims to evaluate the long-term safety and efficacy of the synthetic bone graft OssDsi…
August 16, 2021
Karolinska Development's portfolio company OssDsign launches the synthetic bone graft OssDsign Catalyst on the U.S. market
STOCKHOLM, SWEDEN – August 16, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company OssDsign AB has launched OssDsign Catalyst in the U.S. The product is a synthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surger…
August 10, 2021
OssDsign Partners with Red One Medical to Provide Reconstructive Cranial Solutions and Synthetic Bone Grafts to US Veterans and Military Members
SAVANNAH, Ga., Aug. 10, 2021 /PRNewswire/ -- OssDsign, a global provider of reconstructive implant solutions, has recently entered into an agreement with Red One Medical, a private sector scout of medical innovation for the Department of Veterans Affairs (VA) and Department of Defense...
October 14, 2020
Prestigious publication confirms potential of technology used by Karolinska Development's portfolio company OssDsign
STOCKHOLM, SWEDEN – October 14, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that a scientific article describing the portfolio company OssDsign's unique regenerative implants has been published in the reputable scientific journal PNAS (Proceedings of the National Academy…
September 18, 2020
Karolinska Development’s portfolio company OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market
STOCKHOLM, SWEDEN – September 18, 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has received a notice of allowance from the United States Patent and Trademarks Office (USPTO) concerning the implant design for the company’s product Cranial PSI, th…
OssDsign Frequently Asked Questions
When was OssDsign founded?
OssDsign was founded in 2011.
Who are OssDsign key executives?
OssDsign's key executives are Anders Qvarnström, Simon Cartmell and Morten Henneveld.
How many employees does OssDsign have?
OssDsign has 40 employees.
Who are OssDsign competitors?
Competitors of OssDsign include Graftys, Abyrx and Stroke2Prevent.
Where is OssDsign headquarters?
OssDsign headquarters is located at Uppsala Business Park Rapsgatan 7 Postal Address:, Virdings allé 2, Uppsala.
Where are OssDsign offices?
OssDsign has an office in Uppsala.
How many offices does OssDsign have?
OssDsign has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies